J&J Looks at Third Strike In DePuy Pinnacle Hip Implant Litigation

By Daniel R. Lapinski |   Nov. 27, 2017

For the third time in a row, Johnson & Johnson (J&J) and its subsidiary, DePuy, have been hit with a 9-figure verdict in a bellwether trial involving DePuy’s Pinnacle line of metal-on-metal hip implants.  On November 16, 2017, after a two-month trial, a unanimous jury found the implant manufacturers liable for design defect, negligent design and inadequate warning, among other things.  The $247 million award to the six individual plaintiffs included $168 million in punitive damages against these companies for wanton, reckless and malicious conduct.

Read More

Topics : Johnson & Johnson, depuy pinnacle, hip implant litigation, depuy, metal on metal hip implants, hip implants, bellwether trial, depuy pinnacle hip implant, depuy pinnacle litigation | 0 Comments Read More

Daniel R. Lapinski Appointed Member of Plaintiffs’ Steering Committee In Proton-Pump Inhibitor Products Liability Litigation

By Daniel R. Lapinski |   Aug. 28, 2017

On August 23, 2017, Daniel R. Lapinski was appointed as a member of the Plaintiffs' Steering Committee in In re: Proton-Pump Inhibitor Products Liability Litigation, MDL No. 2789.  The coordinated litigation is currently centralized before the Honorable Claire C. Cecchi, United States District Judge, in the United States District Court for the District of New Jersey.  Proton-Pump Inhibitors (PPIs) are a class of medications commonly used to treat gastroesophageal reflux (GERD), dyspepsia , gastric ulcers and acid peptic disease. The more popular forms of PPIs include Prilosec, Prevacid, Nexium and AcipHex.  Complaints against the manufacturers of these popular medications allege that the drugs are linked to an increased risk of chronic kidney disease and acute kidney injury.

Read More

Topics : Litigation, New Jersey Litigation, plaintiffs steering committee, proton pump inhibitor products liability, products liability litigation | 0 Comments Read More

Will Invokana be the next J&J product to be treated as a mass tort?

By Daniel R. Lapinski |   Nov. 7, 2016

On the heels of the transfer of multiple federal cases alleging that Johnson’s Baby Powder increases the risk of ovarian cancer, J&J now faces the same requests for cases related to another of its products, Invokana.

Read More

Topics : Johnson & Johnson, janssen pharmaceuticals, risks of invokana, invokana, type 2 diabetes, diabetic drug treatments, invokana risks | 0 Comments Read More

Recent Reports Of Side Effects Related To Popular GI Medications May Make Manufacturers Sick To their Stomachs

By Daniel R. Lapinski |   Jul. 21, 2016

Recent studies in several highly regarded medical journals have linked some of the most popular medications on the market for farily common gastrointestinal issues to an increased risk of developing kidney disease.  With over $7 billion in annual sales, Proton Pump Inhibitors (PPIs) are one the most prescribed classes of drugs ever.  Some of the most popular brands of PPIs are:

Read More

Topics : current users of PPIs, Proton Pump Inhibitors, PPIs, gastrointestinal ailments, side effects of gi medications | 0 Comments Read More

    All Blog Posts

    Subscribe to Email Updates

    Featured Blogger

    Daniel R. Lapinski

    Daniel R. Lapinski

    Click Here to Read My Latest Blog Post